Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles

Abstract

In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high‐risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post‐transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker‐directed fashion.

Keywords

• 11q deletion
• anti‐GD2 therapy
• immune checkpoint inhibition
• microRNAs